Press Releases April 23, 2026 04:05 PM

Silvaco Announces Date of First Quarter 2026 Financial Results Conference Call

Silvaco schedules Q1 2026 earnings release and conference call for May 7, 2026

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
SVCO

Silvaco Group, Inc., a semiconductor design software company, announced it will release its financial results for the first quarter ended March 31, 2026, after market close on May 7, 2026. The company will host a conference call to discuss the results and outlook for Q2 2026.

Silvaco Announces Date of First Quarter 2026 Financial Results Conference Call
SVCO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Silvaco provides AI-enabled TCAD, EDA, and SIP solutions for semiconductor design, impacting technology and semiconductor sectors.
  • The company serves diverse markets including automotive, memory, photonics, IoT, and 5G/6G mobile, affecting multiple high-tech industry segments.
  • Q1 financial results and Q2 outlook to be disclosed publicly with opportunity for investors to participate in the conference call.

SANTA CLARA, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- Silvaco Group, Inc. (Nasdaq: SVCO) ("Silvaco" or the "Company"), a provider of TCAD, EDA software, and SIP solutions that enable innovative semiconductor design and digital twin modeling through AI software and automation, will release its financial results for the first quarter ended March 31, 2026, after the market close on Thursday, May 7, 2026. The company will host a conference call at 5:00 p.m. Eastern time to discuss its first quarter 2026 results and second quarter 2026 outlook.

A press release highlighting the Company's results along with supplemental financial results will be available at https://investors.silvaco.com/. An archived replay of the conference call will be available on this website for a limited time after the call. Participants who want to join the call and ask a question may register for the call here to receive the dial-in numbers and unique PIN.

Date: Thursday, May 7, 2026

Time: 5:00 p.m. Eastern time

Webcast: Here (live and replay)

About Silvaco

Silvaco is a provider of AI-enabled TCAD and EDA solutions, and SIP solutions that enable semiconductor design and digital twin modeling through AI software and innovation. Silvaco’s solutions are used for semiconductor and photonics processes, devices, and systems development across display, power devices, automotive, memory, high performance compute, foundries, photonics, internet of things, and 5G/6G mobile markets for complex SoC design. Silvaco is headquartered in Santa Clara, California, and has a global presence with offices located in North America, Europe, Brazil, China, Egypt, Japan, Korea, Singapore, Taiwan, and Vietnam. Learn more at silvaco.com.

Safe Harbor Statement

This press release contains forward-looking statements based on Silvaco Group, Inc.'s current expectations. The words “believe”, “estimate”, “expect”, “intend”, “anticipate”, “plan”, “project”, “will”, and similar phrases as they relate to Silvaco Group, Inc. are intended to identify such forward-looking statements. These forward-looking statements reflect the current views and assumptions of Silvaco Group, Inc. and are subject to various risks and uncertainties that could cause actual results to differ materially from expectations.

Contacts
Investor Relations:
Greg McNiff, investors@silvaco.com

Media Relations:
press@silvaco.com


Risks

  • Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, affecting investor expectations.
  • Global semiconductor market volatility and competition might impact future financial performance.
  • Reliance on technology innovation and market adoption could pose operational risks if market conditions change.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026